The Lung Cancer Research Foundation (LCRF) is pleased to announce its partnership with Israel Cancer Research Fund (ICRF) on ...
Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a ...
Scientists at UC San Francisco have developed a revolutionary cancer treatment that precisely targets tumors with radiation ...
The global in vitro diagnostics market size was reached at USD 83.41 billion in 2024 and is expected to expand around USD 129.14 billion by 2033, with a CAGR of 4.97% from 2024 to 2033. The market is ...
In a pioneering collaboration with AbbVie, Northwestern researchers have discovered a new way to potentially treat cancer by ...
This important study demonstrates the potential of synthetic gene circuits to detect and target aberrant RAS activity in cancer cell lines. The circuit design is novel and the evidence supporting the ...
DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies ...
Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.
Nancy A. Grygiel, Senior Vice President and Chief Compliance Officer at Amgen Inc . (NASDAQ:AMGN), recently sold shares of the company's common stock. According to a filing with the Securities and ...
Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated ...
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...
Global markets have recently experienced a mix of volatility and growth, with U.S. stocks facing challenges from competitive pressures in the AI sector and political uncertainties surrounding tariffs, ...